For the quarter ending 2026-03-31, PDSB had -$5,051,473 decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total operating expenses | 6,521,087 | 6,674,708 | 24,869,251 | - |
| Interest income | 186,814 | 224,659 | 992,582 | - |
| Interest expense | 1,014,783 | 1,112,870 | 4,225,737 | - |
| Benefit from income taxes | 0 | 0 | -1,169,820 | - |
| Net loss | -7,349,056 | -7,562,919 | -9,009,411 | -17,923,175 |
| Stock-based compensation expense | 1,156,495 | 1,158,210 | 1,246,485 | 1,701,911 |
| Issuance of shares in consulting agreements | 0 | 95,000 | 0 | 203,501 |
| Amortization of debt discount | 448,837 | 474,408 | -307,179 | 1,386,606 |
| Loss on retirement of debt | - | -354,166 | -752,838 | - |
| Depreciation expense | 5,459 | 5,459 | 5,459 | 10,918 |
| Finance lease depreciation expense | 9,670 | 9,672 | 9,670 | 19,340 |
| Prepaid expenses and other assets | -764,455 | -4,709,906 | -80,290 | 4,963,760 |
| Accounts payable | 75,904 | -1,606,480 | 683,494 | 2,812,566 |
| Accrued expenses | 516,590 | -1,340,007 | 622,306 | -1,381,286 |
| Operating lease liabilities | - | 0 | - | - |
| Net cash used in operating activities | -4,371,646 | -3,702,585 | -5,916,048 | -18,133,379 |
| Purchase of equipment | - | 0 | 0 | 0 |
| Net cash used in investing activities | - | 0 | 0 | 0 |
| Loan repayment | - | 354,167 | 0 | 18,645,833 |
| Proceeds from issuance of pre-funded warrants | 0 | 1,038,094 | - | - |
| Proceeds from exercise of pre-funded warrants | 0 | 6 | 0 | 94 |
| Proceeds from exercise of stock options | - | 0 | 0 | 0 |
| Proceeds from issuance of pre-funded warrants | - | - | 0 | 1,009,969 |
| Net proceeds from issuance of loan | - | -1,073,089 | 4 | 19,237,880 |
| Proceeds from issuance of warrants | 0 | 3,165,040 | 0 | 2,150,771 |
| Payments of finance lease obligations | 13,198 | 15,806 | 15,451 | 29,862 |
| Loan principal repayment | 1,500,000 | 1,500,000 | 1,000,000 | 4,166,667 |
| Proceeds from issuance of common stock from the sales agreement, net | - | - | 1,256,652 | 1,766,757 |
| Proceeds from issuance of common stock from at-the-market program, net of issuance costs | 833,371 | 4,274,312 | - | - |
| Proceeds from issuance of common stock, net of issuance costs | 0 | 2,714,890 | 0 | 6,994,174 |
| Net cash provided by financing activities | -679,827 | 4,215,902 | 241,205 | 8,317,283 |
| Net increase in cash and cash equivalents | -5,051,473 | 513,317 | -5,674,843 | -9,816,096 |
| Cash and cash equivalents at beginning of period | 26,711,969 | 26,198,652 | 41,689,591 | - |
| Cash and cash equivalents at the end of period | 21,660,496 | 26,711,969 | 26,198,652 | - |
PDS Biotechnology Corp (PDSB)
PDS Biotechnology Corp (PDSB)